Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $1.17 up 1.74% from its previous closing price of $1.15. In other words, the price has increased by $1.74 from its previous closing price. On the day, 0.62 million shares were traded. BTAI stock price reached its highest trading level at $1.2398 during the session, while it also had its lowest trading level at $1.1.
Ratios:
For a deeper understanding of BioXcel Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 17 ’24 when Mehta Vimal sold 2,134 shares for $1.28 per share. The transaction valued at 2,739 led to the insider holds 47,539 shares of the business.
Yocca Frank sold 372 shares of BTAI for $476 on Jun 17 ’24. The Chief Scientific Officer now owns 13,474 shares after completing the transaction at $1.28 per share. On Jun 17 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 372 shares for $1.26 each. As a result, the insider received 470 and left with 5,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 43911036 and an Enterprise Value of 72106064. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.95. Its current Enterprise Value per Revenue stands at 41.063 whereas that against EBITDA is -0.514.
Stock Price History:
Over the past 52 weeks, BTAI has reached a high of $10.43, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is -18.18%, while the 200-Day Moving Average is calculated to be -56.60%.
Shares Statistics:
For the past three months, BTAI has traded an average of 627.82K shares per day and 660350 over the past ten days. A total of 29.93M shares are outstanding, with a floating share count of 29.32M. Insiders hold about 21.88% of the company’s shares, while institutions hold 24.75% stake in the company. Shares short for BTAI as of 1721001600 were 626143 with a Short Ratio of 1.00, compared to 1718323200 on 1489197. Therefore, it implies a Short% of Shares Outstanding of 626143 and a Short% of Float of 2.1999999999999997.
